Adverum Biotechnologies, Inc.
ADVMAdverum Biotechnologies, Inc. (formerly known as Avalanche Biotechnologies) is a publicly traded clinical stage gene therapy company located in Redwood City, California. It is targeting unmet medical needs for serious ocular and rare diseases, including wet age-related macular degeneration (wet AMD).
Drugs in Pipeline
2
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Q4 2026
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
Aflibercept
Neovascular Age-Related Macular Degeneration (nAMD)
6E11 vg/eye of ADVM-022
Diabetic Macular Edema
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Aflibercept | Phase 3 | Neovascular Age-Related Macular Degeneration (nAMD) | - | |
6E11 vg/eye of ADVM-022 | Phase 2 | Diabetic Macular Edema | - | - |
Neovascular Age-Related Macular Degeneration (nAMD)
1 drug in this indication
Diabetic Macular Edema
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)